VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Cutia Therapeutics 科笛集團 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2487) VOLUNTARY ANNOUNCEMENT ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) This announcement is made by Cutia Therapeutics (the “Company ”, together with its subsidiaries, the “Group ”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group. The board of directors (the “Board”) of the Company is pleased to announce that all enrolled patients have completed the Phase I clinical trial of CU-40101 (topical small molecule thyroid hormone receptor agonist liniment), a potential Class I new drug of the Group. The indication of CU-40101 is for the treatment of androgenetic alopecia. CU-40101 contains a potent small molecule thyroid hormone receptor agonist that binds to thyroid receptor in hair follicle cells and induces hair growth. CU-40101 is to be applied to the scalp directly, reducing systemic exposure and the associated adverse effects. CU-40101 is differentiated from currently available androgenetic alopecia treatment in its mechanism of action and the potential to be used in both male and female patients. The Phase I clinical trial of CU-40101 conducted in China was a dose escalation trial to evaluate the safety and tolerability of CU-40101 as a therapeutic agent in promoting hair growth in patients with androgenetic alopecia. Warning: There is no assurance that CU-40101 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. By order of the Board Cutia Therapeutics Zhang Lele Chief Executive Officer and Executive Director Hong Kong, 18 July 2023 As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Huang Xiao, Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.

The release as fetched from its publisher. cutiatx.com ↗